Transgene Biotek Ltd (TRABI) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Transgene Biotek Ltd on NSE and BSE, with an AI summary of each filing.
1. RESIGNATION OF M/S. HARISH GUMMADI & CO., CHARTERED ACCOUNTANTS: The Board took note of the resignation letter dated 03rd November, 2026, submitted by M/s. Harish Gummadi & Co., Chartered ....
Others (Uncategorized) · 04 Nov 2026, 8:49 pm
Transgene Biotek Appoints Ranganath Prasad & Co. as Statutory Auditors Transgene Biotek's Board approved the appointment of M/s. Ranganath Prasad & Co., Chartered Accountants, as Statutory Auditors on 4th Nov'26 to fill a casual vacancy, subject to shareholder approval. The incoming auditor will hold office until the next AGM. This follows the resignation of M/s. Harish Gummadi & Co. on 3rd Nov'26 due to an immediate family medical emergency that constrained their professional bandwidth to complete the limited review for the quarter ended 30th Sep'26 within regulatory deadlines.
Intimation of Resignation of Statutory of Auditors - M/S. Harish Gummadi & Co.., Chartered Accountants.
Change in Auditor · 04 Nov 2026, 7:28 pm
Transgene Biotek Statutory Auditor Resigns Citing Family Medical Emergency M/s Harish Gummadi & Co., Chartered Accountants, resigned as statutory auditors of Transgene Biotek Limited effective 3rd Nov'26, just a day after being appointed on 2nd Nov'26 to fill a casual vacancy. The firm cited an unforeseen family medical emergency that constrained professional availability and prevented completing the limited review for the quarter ended 30th Sep'26 ahead of the 14th Nov'26 regulatory deadline. No audit reports were issued prior to departure, and no material concerns or management-imposed limitations were reported.
1. APPOINTMENT OF STATUTORY AUDITORS TO FILL THE CASUAL VACANCY: The Board of Directors, based on the recommendation of the Audit Committee, has approved the appointment of M/s. Harish ....
Others (Uncategorized) · 02 Nov 2026, 5:24 pm
Transgene Biotek Appoints Harish Gummadi & Co as Statutory Auditors Following Resignation Transgene Biotek's Board approved the appointment of M/s. Harish Gummadi & Co., Chartered Accountants, as Statutory Auditors on 2nd Nov'26 to fill a casual vacancy, subject to shareholder approval. The incoming auditor will hold office until the conclusion of the next AGM. This follows the resignation of M/s. Eswara Rao & Co. effective 28th Oct'26 due to unforeseen personal circumstances, who confirmed no audit work had commenced for the quarter ended 30th Sep'26 and reported no concerns or non-cooperation from management.
Submission of Additional Details Pursuant to BSE Observation -Resignation of Statutory Auditors under Regulation 30 of SEBI (LODR) Regulations, 2015.
Change in Auditor · 01 Nov 2026, 12:53 am
Transgene Biotek Clarifies Statutory Auditor Resignation Following BSE Observations Transgene Biotek Limited submitted additional disclosures following BSE observations regarding the resignation of statutory auditor M/s Vasavi & Co., Chartered Accountants (FRN: 020965S), effective 22nd Sep'26. The auditor, initially appointed on 30th Dec'23 for a term ending 30th Sep'28, resigned due to pre-occupation with other professional assignments and inability to devote sufficient time. The auditor confirmed no other material reasons, audit concerns, or lack of management information existed, with their last submitted limited review covering the quarter ended 30th Jun'26 on 7th Aug'26.
Submission of Additional Details pursuant to BSE Observation -Resignation of Statutory Auditors under Regulation 30 of SEBI (LODR) Regulation, 2015.
Change in Auditor · 01 Nov 2026, 12:49 am
Transgene Biotek Clarifies Statutory Auditor Resignation Due to Capacity Constraints Transgene Biotek Limited submitted detailed disclosures regarding the resignation of statutory auditor M/s. Eswara Rao & Co., effective 28th Oct'26. Appointed on 10th Oct'26 to fill a casual vacancy, the auditor stepped down prior to commencing audit or limited review work for the quarter ended 30th Sep'26. The firm cited unforeseen family medical emergencies affecting key engagement partners, precluding timely completion before the 14th Nov'26 deadline. The auditor confirmed no management non-cooperation, information withholding, or other material audit concerns.
Submission of Additional Details pursuant to BSE Observation -Resignation of Statutory Auditor under Regulation 30 of SEBI (LODR) Regulations, 2015.
Change in Auditor · 31 Oct 2026, 6:43 pm
Transgene Biotek Clarifies Immediate Resignation of Statutory Auditor Eswara Rao & Co. Transgene Biotek submitted disclosures to BSE regarding the resignation of statutory auditor M/s. Eswara Rao & Co. effective 28th Oct'26. Appointed on 10th Oct'26 to fill a casual vacancy, the auditor resigned citing a family medical emergency affecting key partners, preventing completion of the limited review for the quarter ended 30th Sep'26 ahead of the 14th Nov'26 deadline. The auditor confirmed it had not commenced audit work and reported no concerns, non-cooperation, or management-imposed limitations during its tenure.
Intimation of Resignation of Statutory Auditors -M/s. Eswara Rao & Co., Chartered Accountants.
Change in Auditor · 29 Oct 2026, 3:50 pm
Transgene Biotek Statutory Auditors Resign Citing Pre-Occupation Transgene Biotek Limited announced that statutory auditor M/s. Eswara Rao & Co., Chartered Accountants, resigned with immediate effect on 28th Oct'26 due to pre-occupation with other assignments. Appointed on 10th Oct'26 to fill a casual vacancy, the auditor confirmed it had not commenced any audit or limited review work for the quarter ended 30th Sep'26. The firm noted no non-cooperation or material concerns regarding management. Transgene Biotek will initiate steps to appoint a replacement auditor under Companies Act and SEBI LODR norms.
Appointment of Statutory Auditors to fill the Casual Vacancy The Board of Directors, based on the recommendation of the Audit Committee, has approved the appointment of M/s. Eswara Rao ....
Outcome · 10 Oct 2026, 6:08 pm
Transgene Biotek Appoints Eswara Rao & Co. as Statutory Auditors The Board of Directors of Transgene Biotek Limited, at its meeting on 10th Oct'26, approved the appointment of M/s. Eswara Rao & Co., Chartered Accountants (FRN: 000816S), represented by Partner Ms. Karra Pranavi, as Statutory Auditors. The appointment fills the casual vacancy created by the resignation of M/s. Vasavi & Co., Chartered Accountants. The decision is subject to approval by company shareholders at an upcoming general meeting pursuant to the Companies Act, 2013. Required consent and eligibility confirmations were reviewed and noted by the Board.
Statement of Deviation & Variation, 30-09-2026.
Others (Uncategorized) · 04 Oct 2026, 12:08 am
Transgene Biotek Clarifies Non-Applicability of Regulation 32(1) for Q2 FY27 Transgene Biotek informed the BSE that Regulation 32(1) of SEBI LODR Regulations regarding the Statement of Deviation or Variation is not applicable for the quarter ended 30th Sep'26. The company confirmed that no funds were raised through public, rights, preferential issues, or QIPs during the reporting period, rendering deviation disclosures inapplicable. Furthermore, the company noted its inability to submit via XBRL mode due to system restrictions on NIL entries.
Compliance -57(5) Intimation after the end of quarter
Others (Uncategorized) · 04 Oct 2026, 12:05 am
Transgene Biotek Confirms Non-Applicability of SEBI LODR Regulation 57(5) Transgene Biotek Limited confirmed to BSE that Regulation 57(5) of SEBI (LODR) Regulations, 2015, is not applicable to the company for the quarter ended 30th Sep'26. The company stated it has not issued any non-convertible securities, negating requirements for submission of certificates regarding payment obligations or details of unpaid interest, dividend, or principal obligations at the close of the quarter.
Compliance -57(4)
Others (Uncategorized) · 04 Oct 2026, 12:03 am
Transgene Biotek Clarifies Non-Applicability of SEBI Regulation 57 for September 2026 Quarter Transgene Biotek Limited has informed BSE that Regulation 57 of SEBI (LODR) Regulations, 2015, is not applicable to the company for the quarter and half-year ended 30th Sep'26. The company confirmed it holds no outstanding non-convertible securities requiring any interest, dividend, or principal payouts during the period.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 03 Oct 2026, 11:02 pm
Transgene Biotek Non-Applicability Confirmation Under SEBI Large Corporate Framework Transgene Biotek Limited confirmed to BSE on 3rd Oct'26 that it does not meet the specified criteria under SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 to be classified as a "Large Corporate." Consequently, the mandatory debt-security issuance and fundraising provisions are not applicable to the company. The company reported zero outstanding long-term borrowings and held no credit ratings for the preceding financial period, exempting it from Large Corporate compliance and related shortfall penalty frameworks.
Transgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/10/2026 ,inter alia, to consider and approve To consider and approve the ....
Intimation · 03 Oct 2026, 12:27 am
Transgene Biotek Board to Consider New Statutory Auditor Appointment Transgene Biotek has scheduled a Board of Directors meeting on 10th Oct'26 to consider and approve the appointment of M/s. Eswara Rao & Co., Chartered Accountants, as Statutory Auditors. The proposed appointment addresses the casual vacancy created by the resignation of M/s. Vasavi & Co. The company has secured the requisite consent letter and eligibility certificate, and the appointment remains subject to recommendations from the Audit Committee and subsequent approval by shareholders at a general meeting pursuant to Companies Act, 2013, and SEBI regulations.
Intimation Extension of time for holding 36th Annual General Meeting of the Company for the Financial year ended on March 31, 2026.
Annual General Meeting · 25 Sept 2026, 5:23 pm
Intimation of Resignation of Statutory Auditors-M/s. Vasavi & Co., Chartered Accountants (FRN:020965S).
Change in Auditor · 24 Sept 2026, 1:16 am
Transgene Biotek Statutory Auditor Resigns Citing Pre-Occupation Transgene Biotek announced the resignation of its statutory auditor, M/s Vasavi & Co., Chartered Accountants (FRN: 020965S), effective 22nd Sep'26. The auditor resigned due to pre-occupation with other assignments, rendering them unable to devote sufficient time to the company's affairs, with no other material reasons cited. Transgene Biotek stated it will initiate necessary steps to appoint a new statutory auditor in compliance with the Companies Act, 2013, and SEBI LODR Regulations.
Unaudited Financial Results for the quarter ended 30th June 2026.
Financial Result · 07 Aug 2026, 5:25 pm
Transgene Biotek Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 6.0 (+21.2% YoY | +10.1% QoQ) ■ EBITDA: -5.8 (+57.9% YoY | +79.2% QoQ) ■ EBITDA Margin (%): -97.0 (+18260 bps YoY | +41731 bps QoQ) ■ PAT: -38.9 (+10.3% YoY | +14.9% QoQ) ■ EPS (INR): -0.05 (+16.7% YoY | +16.7% QoQ)
Sub: Outcome of the Meeting of the Board of Directors held on August 07, 2026. This has reference to our letter dated 22nd July 2026, Intimating the meeting of the Board of Directors of ....
Outcome · 07 Aug 2026, 5:12 pm
Transgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....
Intimation · 07 Aug 2026, 5:30 am
Compliance - 57(4)
Others (Uncategorized) · 22 Jul 2026, 7:14 pm
Transgene Biotek: Nil Obligation on Non-Convertible Securities for Q1FY27 Transgene Biotek Limited informed BSE on 22-Jul-26 that Regulation 57 of SEBI (LODR) Regulations, 2015 is not applicable for the quarter ended 30-Jun-26. The company confirmed it had no outstanding non-convertible securities for which interest, dividend, or principal payments were due during the period. This filing clarifies that there were no payment obligations related to such instruments for the quarter.
Statement of Deviation & Variation
Others (Uncategorized) · 22 Jul 2026, 7:10 pm
Transgene Biotek: Regulation 32(1) Not Applicable for Q1FY27 Transgene Biotek (SYMBOL: 526139) informed exchanges on 22-Jul'26 that the Statement of Deviation or Variation is not applicable for the quarter ended 30-Jun'26. The company confirmed it did not undertake any public issue, rights issue, preferential issue, or Qualified Institutions Placement (QIP) during the quarter. Therefore, no funds were raised, and there are no proceeds for which a deviation statement under SEBI's Regulation 32(1) would be required. The filing was submitted as a letter due to XBRL limitations on NIL entries.
Compliance -57 (5)
Others (Uncategorized) · 22 Jul 2026, 7:07 pm
Transgene Biotek Confirms No Outstanding Non-Convertible Securities Transgene Biotek Limited informed the BSE on 22-Jul'26 that Regulation 57(5) of SEBI (LODR) Regulations, 2015, is not applicable for the quarter ended 30-Jun'26. The company confirmed it has not issued any non-convertible securities, and consequently, there were no interest, dividend, or principal payment obligations due during the quarter. This filing clarifies that the company holds no such debt instruments on its books as of the specified date.
Audited Financial Results
Financial Result · 29 May 2026, 5:11 pm
Transgene Biotek Reports Widened Losses for Q4 and FY26 For FY26 ended 31 Mar'26, Transgene Biotek reported a consolidated net loss of ₹165.29 lakhs, a significant increase from the ₹67.61 lakh loss in FY25. Total annual income fell to ₹36.11 lakhs from ₹104.42 lakhs YoY. The Q4FY26 net loss was ₹45.70 lakhs versus a ₹71.31 lakh loss in Q4FY25. Finance costs were a major expense driver, surging to ₹106.02 lakhs for the year from ₹24.30 lakhs previously. The auditors issued an unmodified opinion on the financial statements.
This has reference to our letter dated May 13, 2026, The Board of Directors of the Company at their meeting held on May 29, 2026 have resolved as follows: Pursuant to Regulation 33 of ....
Outcome · 29 May 2026, 5:05 pm
Transgene Biotek Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 5.5 (-28.8% YoY | +0.0% QoQ) ■ EBITDA: -28.0 (+48.3% YoY | -455.0% QoQ) ■ EBITDA Margin (%): -514 (+19445 bps YoY | -42165 bps QoQ) ■ PAT: -45.7 (+35.9% YoY | -22.3% QoQ) ■ EPS (INR): -0.06 (+33.3% YoY | -20.0% QoQ)
Transgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve To Consider and approve the ....
Intimation · 29 May 2026, 5:30 am
Transgene Biotek Board Meeting on 29th May'26 for Q4FY26 Results Transgene Biotek has scheduled a Board of Directors meeting for 29th May'26. The primary agenda is to consider and approve the audited standalone and consolidated financial results for the fourth quarter and the financial year ended 31st Mar'26. The meeting will also address any other business matters with the Chair's permission.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 13 Apr 2026, 11:36 pm
Transgene Biotek Confirms It Is Not a Large Corporate Transgene Biotek Limited (BSE: 526139) informed the exchange on 13-Apr'26 that it does not meet the criteria to be classified as a "Large Corporate" under SEBI's circular dated 26-Nov'18. This is based on its financial position as of 31-Mar'26, which shows outstanding borrowings of Rs 0.00 Cr and no applicable credit rating. Consequently, the company is not subject to the mandatory borrowing requirements through debt securities applicable to large corporates.